Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs V 160 (Primary) ; Aluminium phosphate
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 20 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 16 May 2018 Status changed from not yet recruiting to recruiting.
- 05 Apr 2018 New trial record